Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Status:
RECRUITING
Trial end date:
2033-09-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.